Chemical Property of Amenamevir
Chemical Property:
- PKA:12.60±0.70(Predicted)
- PSA：130.85000
- Density:1.360±0.06 g/cm3(Predicted)
- LogP:4.30370
- XLogP3:2.6
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:6
- Exact Mass:482.16239112
- Heavy Atom Count:34
- Complexity:800
- Purity/Quality:
-
99% *data from raw suppliers
Amenamevir *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
- Recent ClinicalTrials:Drug-Drug Interaction Study: ASP2151 and Ciclosporin
- Recent NIPH Clinical Trials:A Study to Investigate the Effects of NPC-06 on the Pharmacokinetics of Amenamevir.
-
Description
Amenamevir is an antiviral inhibitor of herpes simplex virus 1 (HSV-1) helicase-primase complex activity. It inhibits recombinant HSV-1 helicase with an IC50 value of 0.078 μM and recombinant HSV-1 primase when used at concentrations greater than or equal to 0.03 μM. Amenamevir inhibits replication of varicella-zoster virus (VZV), HSV-1, and HSV-2 in human embryonic fibroblast (HEF) cells (EC50s = 0.047, 0.036, and 0.028 μM, respectively) and is not cytotoxic to HEF cells with a 50% cytotoxic concentration (CC50) of greater than 30 μM. Amenamevir also inhibits replication of clinical VZV isolates in HEF cells (EC50s = 0.038-0.10 μM). In vivo, it increases survival of cutaneously HSV-1-infected mice in a zosteriform-spread model of progressive HSV-1 infection (ED50 = 1.9 mg/kg twice per day).
-
Uses
Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL.
